
Subchronic Studies of Pyrilamine in B6C3F1 Mice
Author(s) -
David L. Greenman,
Robert L. Morrissey,
David W. Gaylor,
William T. Allaben
Publication year - 1993
Publication title -
journal of the american college of toxicology
Language(s) - English
Resource type - Journals
ISSN - 0730-0913
DOI - 10.1177/109158189301200404
Subject(s) - pyrilamine , dose , body weight , physiology , medicine , endocrinology , zoology , biology , antagonist , receptor
The purpose of this study was to determine the effects of subchronic exposure to the antihistamine pyrilamine maleate and to establish dosage levels to use in a 2-year chronic study. A 14-day repeated-dose study in male and female B6C3F 1 mice at dietary levels of pyrilamine (as the free base) of 0, 196, 392, 783, 1563, or 3122 ppm revealed no influence on body weight gain and resulted in no deaths, nor abnormal clinical or gross necropsy observations. Parotid gland cell necrosis was more apparent in high-dosage groups than in controls of either gender. Male and female B6C3F 1 mice also were administered pyrilamine for 90 days at dietary concentrations of 0, 375, 750, 1500, 3000, or 6000 ppm. Weight gain was markedly suppressed in the 6000 ppm group, but less so at 1500 and 3000 ppm. Parotid gland cell necrosis was apparent in males receiving 750 ppm pyrilamine and above and in females at 1500 ppm and above. Cytomegaly was noted in the parotid glands of both sexes at midlevel dosages but not in control, low-dosage, or high-dosage animals. It was concluded that 1500 ppm pyrilamine would not be life-threatening to B6C3F 1 mice in a chronic study.